Sibele Inácio Meireles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sibele Inácio Meireles has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Artur Katz
Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, Brazil
2 shared publications - Gustavo dos Santos Fernandes
Hospital Sirio-Libanês, Brasilia, Brazil
2 shared publications - Maria Ignez Braghiroli
Instituto do Cancer do Estado de São Paulo, Brazil
2 shared publications Mariana Vargas Cruz
Hospital Sirio Libanes, Sao Paulo, SP, Brazil
2 shared publications- Paulo Marcelo Hoff
Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil; Universidade de São Paulo, São Paulo, SP, Brazil
2 shared publications - Anabele Stefânia Gomes
Universidade de Brasília, Brazil
1 shared publication
Latest Publications
- 20 December 2023
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (3) , 171-182
Performance of non‐formalin fixed paraffin embedded samples in hybrid capture and amplicon next‐generation sequencing panels
Background: Genomic profiling using next‐generation sequencing (NGS) is fundamental for driving prognostic and therapy in cancer. Formalin‐fixed paraffin embedded (FFPE) tissue is the widely used material, whereas non‐FFPE may represent an alternative. However, studies comparing the NGS performance of non‐FFPE materials to FFPE are still lacking in the literature. The objective of this study was to characterize in non‐FFPE preparations the nucleic acid yield and NGS performance on both a capture‐based and an amplicon‐based NGS platform. NGS quality metrics obtained from non‐FFPE preparations were compared to FFPE.Methods: We analyzed the cellularity and nucleic acid yield in 111 tumors from non‐FFPE preparations. In addition, comprehensive hybrid capture panel sequencing metrics obtained from DNA and RNA libraries were compared between independent non‐FFPE and FFPE samples. A paired comparison between non‐FFPE and FFPE samples was performed to analyze concordance in mutant allele detection using an amplicon panel.Results: The mean target coverage from DNA libraries was 2× higher in non‐FFPE samples than in FFPE. The detection of exogenous DNA was 2.5× higher in non‐FFPE than in FFPE. Conversely, a lower performance was observed in non‐FFPE RNA libraries in comparison to FFPE DNA libraries with no impact in minimum standard cutoffs. The variant allele detection in non‐FFPE was found to be comparable to that of FFPE tumor samples in matched samples.Conclusions: Non‐FFPE was demonstrated to be a suitable material for DNA and RNA library preparations using a comprehensive NGS panel. This is the first study reporting library quality metrics according to the TSO500 analysis pipeline.
- 20 December 2023
- Published by Wiley in Diagnostic Cytopathology
- Vol. 52 (3) , 171-182
Performance of non‐formalin fixed paraffin embedded samples in hybrid capture and amplicon next‐generation sequencing panels
Background: Genomic profiling using next‐generation sequencing (NGS) is fundamental for driving prognostic and therapy in cancer. Formalin‐fixed paraffin embedded (FFPE) tissue is the widely used material, whereas non‐FFPE may represent an alternative. However, studies comparing the NGS performance of non‐FFPE materials to FFPE are still lacking in the literature. The objective of this study was to characterize in non‐FFPE preparations the nucleic acid yield and NGS performance on both a capture‐based and an amplicon‐based NGS platform. NGS quality metrics obtained from non‐FFPE preparations were compared to FFPE.Methods: We analyzed the cellularity and nucleic acid yield in 111 tumors from non‐FFPE preparations. In addition, comprehensive hybrid capture panel sequencing metrics obtained from DNA and RNA libraries were compared between independent non‐FFPE and FFPE samples. A paired comparison between non‐FFPE and FFPE samples was performed to analyze concordance in mutant allele detection using an amplicon panel.Results: The mean target coverage from DNA libraries was 2× higher in non‐FFPE samples than in FFPE. The detection of exogenous DNA was 2.5× higher in non‐FFPE than in FFPE. Conversely, a lower performance was observed in non‐FFPE RNA libraries in comparison to FFPE DNA libraries with no impact in minimum standard cutoffs. The variant allele detection in non‐FFPE was found to be comparable to that of FFPE tumor samples in matched samples.Conclusions: Non‐FFPE was demonstrated to be a suitable material for DNA and RNA library preparations using a comprehensive NGS panel. This is the first study reporting library quality metrics according to the TSO500 analysis pipeline.
- Open Access
Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.
Open AccessNext-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_4) , iv560
Next Generation Sequencing. a Key in Search of Locks?
Aim: Cancer treatment has rapidly evolved in the last decades. Research is mainly directed towards the development of targeted treatments based on individual patient and tumor characteristics. A major recent focus has been the use of sequencing tests that focus on targetable gene alterations. Comprehensive cancer genomic testing using Next-Generation Sequencing (NGS) technology is a very fast and efficient tool which identifies a large number of alterations, some of which may prove to be an important aid in therapeutic decision-making. Many challenges exist in the transition of these technologies from research tool to clinical practice. We aimed to investigate the effectiveness of the current NGS technology as an aid in the oncologic treatment at our institution. Methods: We retrospectively evaluated a cohort of 75 cases of patients with solid tumors treated from Nov. 11 until Feb. 14, who had their tumors sent for a commercially available sequencing assay that utilizes clinical grade NGS. We analyzed all patients for the identification of targetable gene alterations, and whether this result led to a change in treatment and final outcome. Results: Sixty-six patients (88%) were eligible for our analysis (47% female). Sixty-two (94%) had an identifiable mutation, and 11 (17%) received treatment directed by the NGS result. Seven of these 11 patients (63%) had their tumor analyzed by specimens from metastatic sites. Only one patient had a significant tumor response, which was achieved after 2 months of directed treatment, with disease progression 4 months later. The median number of treatment lines prior to the NGS test was 3. Conclusions: Current technology already allows us to identify a large number of mutated genes in cancer specimens. However, most of those mutations are not yet drugable. Our results were somewhat disappointing, with less than 10% response among those few who could receive the directed therapy. However, it is important to note that ours was a heavily pretreated population, and that a significant number of the mutations identified might not be real drivers to the tumor growth. The results of our study suggest that the NGS test is still largely investigational, and that its use as a rescue tool for heavily pretreated patients remains questionable. Disclosure: All authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_4) , iv560
Next Generation Sequencing. a Key in Search of Locks?
Aim: Cancer treatment has rapidly evolved in the last decades. Research is mainly directed towards the development of targeted treatments based on individual patient and tumor characteristics. A major recent focus has been the use of sequencing tests that focus on targetable gene alterations. Comprehensive cancer genomic testing using Next-Generation Sequencing (NGS) technology is a very fast and efficient tool which identifies a large number of alterations, some of which may prove to be an important aid in therapeutic decision-making. Many challenges exist in the transition of these technologies from research tool to clinical practice. We aimed to investigate the effectiveness of the current NGS technology as an aid in the oncologic treatment at our institution. Methods: We retrospectively evaluated a cohort of 75 cases of patients with solid tumors treated from Nov. 11 until Feb. 14, who had their tumors sent for a commercially available sequencing assay that utilizes clinical grade NGS. We analyzed all patients for the identification of targetable gene alterations, and whether this result led to a change in treatment and final outcome. Results: Sixty-six patients (88%) were eligible for our analysis (47% female). Sixty-two (94%) had an identifiable mutation, and 11 (17%) received treatment directed by the NGS result. Seven of these 11 patients (63%) had their tumor analyzed by specimens from metastatic sites. Only one patient had a significant tumor response, which was achieved after 2 months of directed treatment, with disease progression 4 months later. The median number of treatment lines prior to the NGS test was 3. Conclusions: Current technology already allows us to identify a large number of mutated genes in cancer specimens. However, most of those mutations are not yet drugable. Our results were somewhat disappointing, with less than 10% response among those few who could receive the directed therapy. However, it is important to note that ours was a heavily pretreated population, and that a significant number of the mutations identified might not be real drivers to the tumor growth. The results of our study suggest that the NGS test is still largely investigational, and that its use as a rescue tool for heavily pretreated patients remains questionable. Disclosure: All authors have declared no conflicts of interest.